Étiquette : cannabinoïdes

Pharmacotherapy for the Treatment of Cannabis Use Disorder. A Systematic Review, Karli K. Kondo et al., 2020,

Pharmacotherapy for the Treatment of Cannabis Use Disorder. A Systematic Review Karli K. Kondo, PhD; Benjamin J. Morasco, PhD; Shannon M. Nugent, PhD; Chelsea K. Ayers, MPH; Maya E. O’Neil, PhD; Michele Freeman, MPH, and Devan Kansagara, MD, MCR Annals of Internal Medicine, 2020, 172, 398-412. doi : 10.7326/M19-1105   Background : Cannabis use disorder (CUD) is a growing concern, and evidence-based data are needed to inform treatment options. Purpose : To review the benefits and risks of pharmacotherapies for the treatment of CUD. Data Sources : MEDLINE, PsycINFO, Cochrane Database of Systematic Reviews, and clinical trial registries from inception through September 2019. Study Selection : Pharmacotherapy trials [...]

Lire la suite

Cannabinoids : Extraction Methods, Analysis and Physicochemical Characterization, Cristina Lujan RAMIREZ et al., 2019, ,

Cannabinoids : Extraction Methods, Analysis and Physicochemical Characterization Cristina Lujan RAMIREZ, Maria Alejandra FANOVICH, Maria Sandra CHURIO. Studies in Natural Products Chemistry, Chapter 4, 2019, Volume 61, 143-173 (1-44). Doi : 10.1016/B978-0-444-64183-0.00004-X ABSTRACT : A new paradigm has been established in the application of cannabinoids in the last decade. The growing accessibility to different types of Cannabis products and the rise in concern about their health benefits have provoked a rapid expansion of the research interests in phytocannabinoids with promising pharmacological properties. The characterization of the diverse chemotypes of Cannabis sativa, the elucidation of their various structures, and quantification of cannabinoids in the complex [...]

Lire la suite

FDA Approves Clinical Trials for Cannabinoid Drug Designed to Reduce COVID Lung Inflammation, Ralph Ellis, 2020

FDA Approves Clinical Trials for Cannabinoid Drug Designed to Reduce COVID Lung Inflammation Ralph Ellis Medscape, August 21, 2020 The US Food and Drug Administration has approved phase one clinical trials for a synthetic cannabinoid drug designed to treat acute respiratory distress syndrome (ARDS), a life-threatening lung condition which may occur in severe cases of the novel coronavirus, Forbes reported. ARDS can be triggered by over-creation of cytokines, proteins which tell the body to produce more inflammation, Forbes said. The drug going to clinical trials, ARDS-003, would “dampen the cytokine release" and prevent development of ARDS, Tetra Bio-Pharma company CEO and chief regulatory officer Guy Chamberland, MD, [...]

Lire la suite

5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats, Leonardo B.M. Resstel et al., 2009

5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats Leonardo B.M. Resstel, Rodrigo F. Tavares, Sabrina F.S. Lisboa, Sâmia R.L. Joca, Fernando M.A. Corrêa and Francisco S. Guimarães British Journal of Pharmacology, 2009, 156, 181–188; doi : 10.1111/j.1476-5381.2008.00046.x Background and purpose : Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa which induces anxiolytic- and antipsychotic-like effects in rodents. These effects could be mediated by facilitation of the endocannabinoid system or by the activation of 5-HT1A receptors. As either of these mechanisms could promote adaptation to inescapable stress, the aim of the present work [...]

Lire la suite

The nephrologist’s guide to cannabis and cannabinoids, Joshua L. Rein, 2020

The nephrologist’s guide to cannabis and cannabinoids Joshua L. Rein   Purpose of review Cannabis (marijuana, weed, pot, ganja, Mary Jane) is the most commonly used federally illicit drug in the United States. The present review provides an overview of cannabis and cannabinoids with relevance to the practice of nephrology so that clinicians can best take care of patients. Recent findings Cannabis may have medicinal benefits for treating symptoms of advanced chronic kidney disease (CKD) and end-stage renal disease including as a pain adjuvant potentially reducing the need for opioids. Cannabis does not seem to affect kidney function in healthy individuals. However, renal function should be [...]

Lire la suite

Infection VIH et cannabinoides. Etat des lieux et pistes en recherche clinique, Roland Tubiana et Fabienne Caby, RESPADD – GRECC, 2019

Infection VIH et cannabinoides. Etat des lieux et pistes en recherche clinique Roland Tubiana et Fabienne Caby, 24e Rencontres du RESPADD - GRECC, "Usages Cliniques des Cannabinoïdes" 21 juin 2019   (...) Inflammation/ Activation immune et CB Chez les PVVIH traités efficacement, la consommation de CB a été associée: – À des niveaux moins élevés de marqueurs d’inflammation (L B TNF-α+ )/ activation immune (L TCD4+ et CD8+ HLA-DR+CD38+) – A une décroissance plus rapide du niveau d’ADN proviralVIH Mécanismes sous jacents CB (Cannabis Sativa) : > 60 cannabinoides, > 200 non cannabinoides • Cannabinoides: Composant capables d’activer la proteine G couplée aux récepteurs CB1 ou CB2 • Les 2 plus étudiés: Δ9-THC [...]

Lire la suite

Anti-inflammatory Effects of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, on Macrophages From Cystic Fibrosis, Abdullah A. Tarique et al., 2020

Anti-inflammatory Effects of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, on Macrophages From Cystic Fibrosis Abdullah A Tarique, Tama Evron, George Zhang, Mark A Tepper, Mohammed M Morshed, Isabella S G Andersen, Nelufa Begum, Peter D Sly, Emmanuelle Fantino Journal of Cystic Fibrosis, 2020, S1569-1993, (20), 30094-1 doi : 10.1016/j.jcf.2020.03.015. Abstract Background : Lenabasum is an oral synthetic cannabinoid receptor type 2 agonist previously shown to reduce the production of key airway pro-inflammatory cytokines known to play a role in cystic fibrosis (CF). In a double-blinded, randomized, placebo-control phase 2 study, lenabasum lowered the rate of pulmonary exacerbation among patients with CF. The present study was undertaken to investigate anti-inflammatory [...]

Lire la suite

Related Symptoms in People With Multiple Sclerosis : Results From a Retrospective Multicenter Study, Francesco Patti et al., 2020

Related Symptoms in People With Multiple Sclerosis : Results From a Retrospective Multicenter Study Francesco Patti, Clara Grazia Chisari, Claudio Solaro,  Maria Donata Benedetti , Eliana Berra , Assunta Bianco, Roberto Bruno Bossio, Fabio Buttari, Letizia Castelli, Paola Cavalla , Raffaella Cerqua, Gianfranco Costantino, Claudio Gasperini, Angelica Guareschi, Domenico Ippolito, Roberta Lanzillo, Giorgia Teresa Maniscalco, Manuela Matta, Damiano Paolicelli, Loredana Petrucci, Simona Pontecorvo, Isabella Righini, Margherita Russo, Francesco Saccà, Giovanna Salamone, Elisabetta Signoriello, Gabriella Spinicci, Daniele Spitaleri, Eleonora Tavazzi, Maria Trotta, Mauro Zaffaroni, Mario Zappia, SA.FE. group Doi : 10.1007/s10072-020-04413-6 Abstract Introduction : The approval of 9-δ-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sativex®) in Italy as an add-on medication for the management of moderate to severe spasticity in multiple sclerosis (MS) has provided a new opportunity for MS patients with drug-resistant spasticity. We aimed [...]

Lire la suite

Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson’s disease, Isabel Espadas et al., 2020

Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease Isabel Espadas, Ettel Keifman, Cristina Palomo-Garo Sonia Burgaz, Concepción García, Javier Fernández-Ruiz, Rosario Moratalla Neurobiology of Disease, 2020, 141, 104892 doi : 10.1016/j.nbd.2020.104892   A B S T R A C T The antioxidant and CB2 receptor agonist properties of Δ9-tetrahydrocannabivarin (Δ9-THCV) afforded neuroprotection in experimental Parkinson's disease (PD), whereas its CB1 receptor antagonist profile at doses lower than 5 mg/kg caused anti-hypokinetic effects. In the present study, we investigated the anti dyskinetic potential of Δ9-THCV (administered i.p. at 2 mg/kg for two weeks), which had not been investigated before. This objective was investigated [...]

Lire la suite

Report colloque UFCM – I Care, 2020

Cette année, nous avions prévu que le 9e colloque international se déroulerait en juin, chez nous, à Strasbourg et qu’il aborderait la thématique de la recherche sur les cannabinoïdes et les cancers. Aux vues des circonstances de ce début d’année 2020, nous avons pris la décision de reporter cet évènement à une date encore inconnue. Nous allons faire au mieux pour maintenir notre programme. Vous trouverez de plus amples détails dans le communiqué ci-dessous.

Lire la suite